9  0.04 (0.45%)		10-03 16:00
Open: 8.755 High: 9 Volume: 52		Pre. Close: 8.96 Low: 8.755 Market Cap: 44(M)

Short term
Mid term
Targets	6-month :	11.36	1-year :	13.27
Resists	First :	9.72	Second :	11.36
Pivot price	9.14
Supports	First :	8.56	Second :	7.84
MAs	MA(5) :	8.83	MA(20) :	9.14
	MA(100) :	9.02	MA(250) :	8.83
MACD	MACD :	-0.1	Signal :	0
%K %D	K(14,3) :	26	D(3) :	16.9
RSI	RSI(14): 49
52-week	High :	10.03	Low :	7.11

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ DXR ] has closed above bottom band by 32.7%. Bollinger Bands are 10.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	8.8 - 8.85	8.85 - 8.89
Low:	8.51 - 8.58	8.58 - 8.63
Close:	8.68 - 8.78	8.78 - 8.87

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

Fri, 27 Sep 2024
Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device - GlobeNewswire

Wed, 25 Sep 2024
(DXR) Long Term Investment Analysis - Stock Traders Daily

Thu, 19 Sep 2024
Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024 - GlobeNewswire

Thu, 19 Sep 2024
Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024 - StockTitan

Thu, 12 Sep 2024
Newly Published Review Highlights the Pivotal Role of - GlobeNewswire

Thu, 05 Sep 2024
Daxor Corporation Receives $300K Matching Fund Award From Launch Tennessee - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	0 (M)
Shares Float	5 (M)
Held by Insiders	2.1e+006 (%)
Held by Institutions	56.5 (%)
Shares Short	9 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	1 %
Operating Margin	94 %
Return on Assets (ttm)	-419.3 %
Return on Equity (ttm)	-1.4 %
Qtrly Rev. Growth	154210 %
Gross Profit (p.s.)	0
Sales Per Share	0.03
EBITDA (p.s.)	0
Qtrly Earnings Growth	1.1 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-2 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	265.36
Price to Cash Flow	-0.74

Dividend	0
Forward Dividend	14840
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.